Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cystinol N is an herbal medicinal product developed by Schaper & Bruemmer for the treatment of inflammatory diseases of the urinary tract, such as cystitis and irritable bladder. It is a combination therapy consisting of bearberry leaf extract (*Arctostaphylos uva-ursi*) and goldenrod herb extract (*Solidago virgaurea*). The bearberry component contains the glycoside arbutin, which is converted into hydroquinone in the urinary tract, providing direct antibacterial activity against common pathogens like *E. coli*. The goldenrod component acts as a diuretic, anti-inflammatory, and antispasmodic agent, primarily by inhibiting the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. This dual action helps to eliminate bacteria while flushing the urinary tract and reducing pain and irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cystinol N.